Rheonix announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance to its automated workstation software and molecular test for sexually transmitted infections (STIs).
The Encompass MDx workstation enables scalable, multiplexed sample-to-answer detection, simplifying laboratory workflows.
The Rheonix STI triplex assay and male urine collection kit is approved for simultaneous detection and differentiation of Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis.
